LEO PHARMA INC is recalling approximately 11,407 units of Adbry (tralokinumab-ldrm) 300 mg/2mL injections because a wool fiber was found inside one unit. While only one unit was reported to contain the fiber, the issue creates a lack of assurance that the entire batch remains sterile. Adbry is used to treat moderate-to-severe atopic dermatitis (eczema) and was distributed nationwide in the United States.
The presence of foreign particulate matter like wool fiber in an injectable medication can compromise sterility, potentially leading to serious infections or localized inflammatory reactions at the injection site.
You have 2 options:
Rx only; Manufactured by LEO Pharma A/S in Denmark; Distributed by LEO Pharma Inc.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.